SCHEMBL30766142

SCHEMBL30766142

CCCCOC(=O)Cn1c(N2CCn3c(nnc3C(F)(F)F)C2)ncc(Br)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.40
P2RY12 Q9H244 1/20 0.37
LMNA P02545 5/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
DPP4 P27487 6/20 0.34
AMY1A P0DUB6 1/20 0.34
PTPN1 P18031 1/20 0.34
CYP8B1 Q9UNU6 3/20 0.33
DPP8 Q6V1X1 2/20 0.33
SMO Q99835 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765514 0.80 ALDH1A1 (0.48) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30765505 0.77 GAA (0.34) HDAC6P2RY12GAAL3MBTL1MEN1
SCHEMBL30766019 0.76 LMNA (0.54) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30765839 0.69 MEN1 (0.49) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30765661 0.69 MEN1 (0.48) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30765447 0.67 L3MBTL1 (0.65) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30766020 0.67 MEN1 (0.46) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30765740 0.66 MEN1 (0.45) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30765592 0.65 L3MBTL1 (0.50) LMNATSHRMAPK1NPSR1ALDH1A1
SCHEMBL30765500 0.62 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed